Key result
High Sensitive Troponin I was significantly better and faster than echocardiography at detecting early cardiotoxicity in breast cancer patients receiving neoadjuvant CAF therapy (p=0.002).
Why the study?
Echocardiography has limitations in measuring chemotherapy cardiotoxicity in left locally advanced breast cancer with large ulcer, prompting evaluation of HsTnI and erCRP as accessible alternative predictors.
Do HsTnI and erCRP predict cardiotoxicity better than echocardiography in locally advanced breast cancer patients receiving neoadjuvant CAF therapy?
Observational (n=23)
No
Do HsTnI and erCRP predict cardiotoxicity better than echocardiography in locally advanced breast cancer patients receiving neoadjuvant CAF therapy?
p-value: p=0.002
HsTnI is a faster and potentially better alternative to echocardiography for early detection of chemotherapy-induced cardiotoxicity in breast cancer patients.
May support earlier cardiotoxicity surveillance with HsTnI during neoadjuvant CAF; leaves open randomized confirmation before practice change.
The limitation of echocardiography to measure chemotherapy cardiotoxicity at left locally advanced breast cancer with large ulcer is still serious problem. HsTnI and erCRP are biomarkers to detect cardiotoxicity that are cheap, easy to examine and available at Dr.Soetomo Hospital Surabaya. This study was to compare HsTnI, erCRP and echocardiography as cardiotoxicity predictors in locally advanced breast cancer with neoadjuvant CAF therapy. This study used one group pretest and posttest design among 23 locally advanced breast cancer patients. All patients underwent echocardiography, HsTnI, and erCRP examinations before and after 3 times chemotherapy and compared. The average age was 49.78±8.7. Statistically significant decrease in LVEF was found after treatment (67.98%±4.06 and 64.07%±3.53, p=0.000). HsTnI was significantly increased after treatment (0.007 µg/mL±0.004 and 0.043 µg/mL±0.051 p=0.000). erCRP was significantly decreased after treatment (1.043mg/dL±0.913 and 0.573mg/dL±0.444 p=0.044). Decreased LVEF and increased HsTnI was compared by its cardiotoxic cut-off. HsTnI was significantly better and faster to detect cardiotoxicity (0.033±0.051 p=0.002). In conclusion, strong correlation is present in the detection of cardiotoxicity between HsTnI and LVEF. HsTnI is faster than echocardiography, and could be alternative diagnostic to detect early cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Hidayat et al. (2020) conducted an observational in Locally advanced breast cancer (n=23). High Sensitive Troponin I (HsTnI) and Extended Range C-Reactive Protein (erCRP) vs. Echocardiography (LVEF) was evaluated on Detection of cardiotoxicity (p=0.002). High Sensitive Troponin I was significantly better and faster than echocardiography at detecting early cardiotoxicity in breast cancer patients receiving neoadjuvant CAF therapy (p=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: